This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Merck & Company (MRK) Gets a Buy from RBC Capital

Tipranks - Tipranks - Thu Aug 6, 7:02AM CDT

RBC Capital analyst Trung Huynh reiterated a Buy rating on Merck & Company yesterday and set a price target of $142.00. The company’s shares closed yesterday at $128.00.

Claim 55% Off TipRanks

According to TipRanks, Huynh is a 5-star analyst with an average return of 21.6% and a 74.65% success rate. Huynh covers the Healthcare sector, focusing on stocks such as Merck & Company, Pfizer, and Bristol-Myers Squibb.

In addition to RBC Capital, Merck & Company also received a Buy from Wells Fargo’s Mohit Bansal in a report issued today. However, on July 22, Bernstein maintained a Hold rating on Merck & Company (NYSE: MRK).

See the top stocks recommended by analysts >>

Based on Merck & Company’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $16.29 billion and a GAAP net loss of $4.24 billion. In comparison, last year the company earned a revenue of $15.62 billion and had a net profit of $5.08 billion

Read More on MRK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).